EDP 305

DRUG3 trials

Sponsors

Enanta Pharmaceuticals, Inc

Conditions

NASHNASH - Nonalcoholic SteatohepatitisPresumptive NAFLD

Phase 1

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

CompletedNCT02918929

Enanta Pharmaceuticals, IncPresumptive NAFLD

Start: 2016-09-30End: 2017-06-30Updated: 2017-08-21

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

CompletedNCT03207425

Enanta Pharmaceuticals, IncNASH

Start: 2017-06-14End: 2017-09-19Updated: 2017-11-06

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

CompletedNCT03213145

Enanta Pharmaceuticals, IncNASH - Nonalcoholic Steatohepatitis

Start: 2017-07-11End: 2017-09-07Updated: 2017-11-06